Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation
Institute for Clinical and Experimental Medicine
Institute for Clinical and Experimental Medicine
St. Jude Children's Research Hospital
University of Arizona
Baylor College of Medicine
Case Comprehensive Cancer Center
Fred Hutchinson Cancer Center